ArticleDrug design, development and therapy2025
Enhanced Nutritional Support May Ameliorate Rivaroxaban-Related Rapid Renal Function Decline: New Insights from a Real-World Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Aim to compare the effects of rivaroxaban and warfarin on rapid renal function decline. Methods: 8842 patients from the Tianjin Health and Medical Data Platform, with a 2.3 years median follow-up (interquartile range,1.5-3.4), were assigned to either the warfarin group (n = 3913) or rivaroxaban group (n = 4929). Logistic models, inverse probability of treatment weighting(IPTW), and propensity score-matched (PSM) analyses were employed to compare the risk of rapid renal function decline associated with rivaroxaban versus warfarin. The multivariable fractional polynomial interaction(MFPI) was used to investigate interactions between continuous variables and the adverse outcome. Restricted cubic splines(RCS) were applied to assess the relationship between the prognostic nutritional index (PNI) score and the adverse outcome. Results: Rivaroxaban was associated with an increased risk of rapid renal function decline compared with warfarin in both the univariate (odds ratio [OR], 1.24; 95% confidence interval [CI], 1.14-1.36; Conclusion: Rivaroxaban was associated with a higher risk of rapid renal function decline than warfarin. Enhanced nutritional support may help mitigate this adverse outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.